Heart and Vessels

, Volume 26, Issue 3, pp 274–281 | Cite as

Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects

  • Tsuyoshi Shiga
  • Takanori Tanaka
  • Shin Irie
  • Nobuhisa Hagiwara
  • Hiroshi Kasanuki
Original Article


The aim of this phase I, dose-escalating study was to evaluate the pharmacokinetics, electrocardiographic effect and safety of amiodarone after a single intravenous administration in Japanese subjects. Thirty-two healthy Japanese male volunteers (20–32 years) were randomized to three single-dose groups (1.25, 2.5 and 5.0 mg/kg). In each group, six (1.25 mg/kg) or ten (2.5 and 5.0 mg/kg) subjects received a single 15-min infusion of intravenous amiodarone, and two subjects received glucose solution as control. The pharmacokinetic profile, blood pressure and electrocardiographic analyses were obtained on a timely basis after up to 77 days. The maximum plasma concentration (C max) and area under the concentration-time curve (AUC0–96) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C max was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC0-96 was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively. A long serum half-life (>14 days) was observed for amiodarone and desethylamiodarone. PR intervals were prolonged at 15 min (0.16 ± 0.0.1 vs. 0.15 ± 0.01 s, p = 0.03) and 18 min (0.17 ± 0.01 vs. 0.15 ± 0.01 s, p = 0.03) with the 5.0 mg/kg dose compared with baseline. No other significant changes in electrocardiographic parameters, pulse rate or blood pressure were observed. A needle-pain-induced vasovagal effect appeared in a volunteer, and three volunteers experienced pain at the drug infusion site. After a single infusion of amiodarone at doses of 1.25–5.0 mg/kg, serum concentrations increased in a dose-dependent manner. A single intravenous amiodarone dose barely affected the electrocardiographic parameters and was well tolerated.


Amiodarone Desethylamiodarone Pharmacokinetics Healthy subjects 



The authors thank Stephanie Blick and Nicola Van Aardt of Wolters Kluwer Health Medical Communications, who provided assistance with the preparation of the manuscript. This study was supported by Taisho-Sanofi Synthelabo Co., Ltd. (Sanofi-Aventis KK, Tokyo, Japan).


  1. 1.
    Podrid PJ (1995) Amiodarone: reevaluation of an old drug. Ann Intern Med 122:689–700PubMedGoogle Scholar
  2. 2.
    Shiga T, Wakaumi M, Imai T, Suzuki T, Hosaka F, Yamada Y, Matsuda N, Shoda M, Sugiura R, Hagiwara N, Kasanuki H (2002) Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 66:600–604PubMedCrossRefGoogle Scholar
  3. 3.
    Shiga T, Wakaumi M, Matsuda N, Shoda M, Hagiwara N, Sato K, Kasanuki H (2001) Amiodarone-induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. Jpn Circ J 65:958–960PubMedCrossRefGoogle Scholar
  4. 4.
    Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H (2007) Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 71:1610–1616PubMedCrossRefGoogle Scholar
  5. 5.
    Suzuki S, Yamashita T, Otsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Yamazaki T, Aizawa T (2009) Treatment strategy and clinical outcomes in Japanese patients with atrial fibrillation. Heart Vessels 24:287–293PubMedCrossRefGoogle Scholar
  6. 6.
    Takahashi A, Shiga T, Shoda M, Tanizaki K, Manaka T, Ejima K, Kasanuki H, Hagiwara N (2010) Gender difference in arrhythmic occurrences in patients with nonischemic dilated cardiomyopathy and implantable cardioverter-defibrillator. Heart Vessels 25:150–154PubMedCrossRefGoogle Scholar
  7. 7.
    Chow MS (1996) Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 30:637–643PubMedGoogle Scholar
  8. 8.
    Vadiei K, Troy S, Korth-Bradley J, Chiang ST, Zimmerman JJ (1997) Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol 37:610–617PubMedGoogle Scholar
  9. 9.
    Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72:45F–50FPubMedCrossRefGoogle Scholar
  10. 10.
    Vadiei K, O’Rangers EA, Klamerus KJ, Kluger J, Kazierad DJ, Leese PT, Chow MS, Zimmerman JJ (1996) Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol 36:720–727PubMedGoogle Scholar
  11. 11.
    Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I (2001) Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 103:1317–1324PubMedGoogle Scholar
  12. 12.
    Kodama I, Kamiya K, Toyama J (1999) Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84:20R–28RPubMedCrossRefGoogle Scholar
  13. 13.
    Ikeda N, Nademanee K, Kannan R, Singh BN (1984) Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue concentrations. Am Heart J 108:890–898PubMedCrossRefGoogle Scholar
  14. 14.
    Desai AD, Chun S, Sung RJ (1997) The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 127:294–303PubMedGoogle Scholar
  15. 15.
    Morady F, DiCarlo LA Jr, Krol RB, Baerman JM, de Buitleir M (1986) Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 7:148–157PubMedCrossRefGoogle Scholar
  16. 16.
    Cinelli P, Romano S, Castaldo G, de Scalzi M, Citi S, de Leonardis V (1984) Computerized M-mode echocardiography in the assessment of cardiovascular effects during intravenous administration of amiodarone. Methods Find Exp Clin Pharamcol 6:27–32Google Scholar
  17. 17.
    Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M, Grolleau R (1988) A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 9:142–148PubMedGoogle Scholar
  18. 18.
    Remme WJ, Kruyssen HA, Look MP, van Hoogenhuyze DC, Krauss XH (1991) Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J 122(1 Pt 1):96–103Google Scholar
  19. 19.
    Cushing DJ, Adams MP, Cooper WD, Zhang B, Lipicky RJ, Kowey PR (2009) Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol 104:1152–1157PubMedCrossRefGoogle Scholar
  20. 20.
    Kowey PR, Marinchak RA, Rials SJ, Filart RA (1997) Intravenous amiodarone. J Am Coll Cardiol 29:1190–1198PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Tsuyoshi Shiga
    • 1
  • Takanori Tanaka
    • 2
  • Shin Irie
    • 2
  • Nobuhisa Hagiwara
    • 1
  • Hiroshi Kasanuki
    • 1
    • 3
  1. 1.Department of CardiologyTokyo Women’s Medical UniversityTokyoJapan
  2. 2.Medical Co. LTA Clinical Pharmacology CenterFukuokaJapan
  3. 3.Faculty of Science and EngineeringWaseda UniversityTokyoJapan

Personalised recommendations